Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash from Investing Activities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Cash from Investing Activities for 13 consecutive years, with -$101000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 46.38% to -$101000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$292000.0, a 104.2% decrease, with the full-year FY2025 number at -$292000.0, down 104.2% from a year prior.
  • Cash from Investing Activities was -$101000.0 for Q4 2025 at Niagen Bioscience, down from -$24000.0 in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of -$2000.0 in Q4 2021 to a low of -$265000.0 in Q2 2021.
  • A 5-year average of -$66050.0 and a median of -$43500.0 in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 8500.0% in 2022, then soared 94.12% in 2023.
  • Niagen Bioscience's Cash from Investing Activities stood at -$2000.0 in 2021, then crashed by 8500.0% to -$172000.0 in 2022, then skyrocketed by 87.79% to -$21000.0 in 2023, then plummeted by 228.57% to -$69000.0 in 2024, then plummeted by 46.38% to -$101000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Cash from Investing Activities are -$101000.0 (Q4 2025), -$24000.0 (Q3 2025), and -$135000.0 (Q2 2025).